125 related articles for article (PubMed ID: 26173500)
1. Deletion of Exons 3 through 5 of ABCG2 causes the Jr(a-) phenotype in a West African woman.
Saison C; Cartron JP; Arnaud L
Transfusion; 2015 Nov; 55(11):2766-7. PubMed ID: 26173500
[No Abstract] [Full Text] [Related]
2. A new ABCG2 null allele with a 27-kb deletion including the promoter region causing the Jr(a-) phenotype.
Ogasawara K; Osabe T; Suzuki Y; Tsuneyama H; Isa K; Kawai M; Obara K; Ogiyama Y; Ito S; Uchikawa M; Satake M; Tadokoro K
Transfusion; 2015 Jun; 55(6 Pt 2):1467-71. PubMed ID: 25522810
[TBL] [Abstract][Full Text] [Related]
3. ABCG2 null alleles define the Jr(a-) blood group phenotype.
Zelinski T; Coghlan G; Liu XQ; Reid ME
Nat Genet; 2012 Jan; 44(2):131-2. PubMed ID: 22246507
[TBL] [Abstract][Full Text] [Related]
4. Molecular analysis of immunized Jr(a-) or Lan- patients and validation of a high-throughput genotyping assay to screen blood donors for Jr(a-) and Lan- phenotypes.
Haer-Wigman L; Ait Soussan A; Ligthart P; de Haas M; van der Schoot CE
Transfusion; 2014 Jul; 54(7):1836-46. PubMed ID: 24456066
[TBL] [Abstract][Full Text] [Related]
5. Defining the Jr(a-) phenotype in the Japanese population.
Tanaka M; Kamada I; Takahashi J; Kimura K; Matsukura H; Tani Y
Transfusion; 2014 Feb; 54(2):412-7. PubMed ID: 23713577
[TBL] [Abstract][Full Text] [Related]
6. Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior.
Saison C; Helias V; Ballif BA; Peyrard T; Puy H; Miyazaki T; Perrot S; Vayssier-Taussat M; Waldner M; Le Pennec PY; Cartron JP; Arnaud L
Nat Genet; 2012 Jan; 44(2):174-7. PubMed ID: 22246505
[TBL] [Abstract][Full Text] [Related]
7. Ethnic differences in ATP-binding cassette transporter, sub-family G, member 2 (ABCG2/BCRP): genotype combinations and estimated functions.
Sakiyama M; Matsuo H; Takada Y; Nakamura T; Nakayama A; Takada T; Kitajiri S; Wakai K; Suzuki H; Shinomiya N
Drug Metab Pharmacokinet; 2014; 29(6):490-2. PubMed ID: 24869748
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
9. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
[TBL] [Abstract][Full Text] [Related]
10. An update on the JR blood group system.
Castilho L
Immunohematology; 2019 Jun; 35(2):43-44. PubMed ID: 31246485
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.
Tamura M; Kondo M; Horio M; Ando M; Saito H; Yamamoto M; Horio Y; Hasegawa Y
Nagoya J Med Sci; 2012 Feb; 74(1-2):133-40. PubMed ID: 22515119
[TBL] [Abstract][Full Text] [Related]
12. The JR blood group system: identification of alleles that alter expression.
Hue-Roye K; Zelinski T; Cobaugh A; Lomas-Francis C; Miyazaki T; Tani Y; Westhoff CM; Reid ME
Transfusion; 2013 Nov; 53(11):2710-4. PubMed ID: 23438071
[TBL] [Abstract][Full Text] [Related]
13. Two novel ABCG2 alleles resulting in a Jr(a-) phenotype.
Berardi P; Cote J; Vege S; Aeschlimann J; Cserti-Gazdewich C; Westhoff CM
Transfusion; 2017 Nov; 57(11):2811-2812. PubMed ID: 28836283
[No Abstract] [Full Text] [Related]
14. ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype response to medical therapy or need for surgeryin Hungarian patients with inflammatory bowel diseases.
Fischer S; Lakatos PL; ; Lakatos L; Kovacs A; Molnar T; Altorjay I; Papp M; Szilvasi A; Tulassay Z; Osztovits J; Papp J; Demeter P; Schwab R; Tordai A; Andrikovics H
Scand J Gastroenterol; 2007 Jun; 42(6):726-33. PubMed ID: 17505995
[TBL] [Abstract][Full Text] [Related]
15. Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch population.
Bosch TM; Kjellberg LM; Bouwers A; Koeleman BP; Schellens JH; Beijnen JH; Smits PH; Meijerman I
Am J Pharmacogenomics; 2005; 5(2):123-31. PubMed ID: 15813675
[TBL] [Abstract][Full Text] [Related]
16. ABCG2 polymorphisms, 34G>A and 421C>A in a Korean population: analysis and a comprehensive comparison with other populations.
Kim KA; Joo HJ; Park JY
J Clin Pharm Ther; 2010 Dec; 35(6):705-12. PubMed ID: 21054463
[TBL] [Abstract][Full Text] [Related]
17. Genetic analysis of ABCG2 gene C421A polymorphism with gout disease in Chinese Han male population.
Wang B; Miao Z; Liu S; Wang J; Zhou S; Han L; Meng D; Wang Y; Li C; Ma X
Hum Genet; 2010 Feb; 127(2):245-6. PubMed ID: 19921266
[No Abstract] [Full Text] [Related]
18. Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population.
Bäckström G; Taipalensuu J; Melhus H; Brändström H; Svensson AC; Artursson P; Kindmark A
Eur J Pharm Sci; 2003 Apr; 18(5):359-64. PubMed ID: 12694888
[TBL] [Abstract][Full Text] [Related]
19. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
[TBL] [Abstract][Full Text] [Related]
20. A novel ABCG2 variant causing Jr(a-) phenotype.
Kwon SS; Yun YE; Kim NH; Suh EJ; Kim SK; Kim S
Transfusion; 2024 Apr; 64(4):E9-E10. PubMed ID: 38361420
[No Abstract] [Full Text] [Related]
[Next] [New Search]
